anastrozole has been researched along with s 1033 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dowsett, M; Dunbier, A; Ghazoui, Z; Martin, LA; Pancholi, S; Weigel, MT | 1 |
1 review(s) available for anastrozole and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for anastrozole and s 1033
| Article | Year |
|---|---|
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoadjuvant Therapy; Neoplasm Proteins; Nitriles; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Signal Transduction; Triazoles | 2012 |